The extraordinary advancements made in DNA sequencing technologies over the past few years have led to the elucidation of \~10,000^[@R1]-[@R13]^ individual human genomes (30x or greater base coverage) from different ethnicities and using different technologies^[@R2]-[@R13]^ and at a fraction of the cost^[@R10]^ of sequencing the original human reference genome^[@R14],[@R15]^. While this is a monumental achievement, the vast majority of these genomes have excluded a very important element of human genetics. Individual human genomes are diploid in nature, with half of the homologous chromosomes being derived from each parent. The context in which variations occur on each individual chromosome can have profound effects on the expression and regulation of genes and other transcribed regions of the genome^[@R16]^. Further, determining if two potentially detrimental mutations occur within one or both alleles of a gene is of paramount clinical importance.

Almost all recent human genome sequencing has been performed on short read-length (\<200 bp), highly parallelized systems starting with hundreds of nanograms of DNA. These technologies are excellent at generating large volumes of data quickly and economically. Unfortunately short reads, often paired with small mate-gap sizes (500b-10kb), eliminate most SNP phase information beyond a few kilobases^[@R8]^. Population based genotype data has been used successfully to assemble short read data into long haplotype blocks^[@R3]^, however these methods suffer from higher error rates and have difficulty phasing rare variants^[@R17]^. Using pedigree information^[@R18]^ or combining it with population data provides additional phasing power, however no combination of these methods are able to resolve *de-novo* mutations^[@R17]^.

Currently four personal genomes, J. Craig Venter^[@R19]^, a Gujarati Indian (HapMap sample NA20847)^[@R11]^, and two Europeans (Max Planck One (MP1)^[@R13]^ and HapMap Sample NA12878^[@R20]^) which have been sequenced and assembled as diploid. All have involved cloning long DNA fragments in a process similar to that used for the construction of the human reference genome^[@R14],[@R15]^. While these processes generate long phased contigs (N50s of 350 kb^[@R19]^, 386 kb^[@R11]^, 1 Mb^[@R13]^, and full-chromosome haplotypes in combination with parental genotypes^[@R20]^) they require a large amount of initial DNA, extensive library processing, and are currently too expensive^[@R11]^ to use in a routine clinical environment. Additionally, several reports have recently demonstrated whole chromosome haplotyping through direct isolation of metaphase chromosomes^[@R21]-[@R24]^. These methods have yet to be used for whole genome sequencing and require preparation and isolation of whole metaphase chromosomes, which can be challenging for some clinical samples. In this paper, we introduce Long Fragment Read (LFR) technology, a process that enables genome sequencing and haplotyping at a clinically relevant cost, quality and scale.

Long Fragment Read technology {#S1}
=============================

The LFR approach can generate long-range phased SNPs because it is conceptually similar to single molecule sequencing of fragments 10-1000 kb^[@R25]^ in length. This is achieved by the stochastic separation of corresponding long parental DNA fragments into physically distinct pools followed by subsequent fragmentation to generate shorter sequencing templates ([Fig. 1a](#F1){ref-type="fig"}). The same principles are used in aliquoting fosmid clones^[@R11],[@R13]^. As the fraction of the genome in each pool decreases to less than a haploid genome, the statistical likelihood of having a corresponding fragment from both parental chromosomes in the same pool dramatically diminishes^[@R25]^. For example, 0.1 genome equivalents (300 Mb) per well yields an approximately 10% chance that two fragments will overlap and a 50% chance those fragments will be derived from separate parental chromosomes. The end result is an approximately 5% overall chance that a particular well will be uninformative for a given fragment. Likewise, the more individual pools interrogated the greater number of times a fragment from the maternal and paternal homologs will be analysed in separate pools. The current version of LFR uses a 384-well plate with 10-20% of a haploid genome in each well, yielding a theoretical 19-38x physical coverage of both the maternal and paternal alleles of each fragment (see [Supplementary Materials](#SD2){ref-type="supplementary-material"} and [Supplementary Table 1](#SD5){ref-type="supplementary-material"} for an explanation of how this amount of material was selected). This high initial DNA redundancy of 19-38x versus recently described strategies using fosmid pools of 3x^[@R11]^ or 6x^[@R13]^ ensures complete genome coverage and higher variant calling and phasing accuracy.

To prepare LFR libraries in a high-throughput manner we developed an automated process that performs all LFR-specific steps in the same 384-well plate. First, a highly uniform amplification using a modified, phi29 polymerase-based, multiple displacement amplification (MDA)^[@R26]^ is performed to replicate each fragment about 10,000 times. Next, through a process of five enzymatic steps within each well, without intervening purification steps, DNA is fragmented and ligated with barcode adapters. Briefly, long DNA molecules are processed to blunt ended 300-1,500 bp fragments through the novel process of Controlled Random Enzymatic fragmenting (CoRE) ([Supplementary Methods](#SD3){ref-type="supplementary-material"} and [Supplementary Figures 2](#SD4){ref-type="supplementary-material"} and [3](#SD4){ref-type="supplementary-material"}). Unique 10-base Reed-Solomon^[@R27]^ error correcting barcode adapters ([Supplementary Figure 4](#SD4){ref-type="supplementary-material"}) are then ligated to fragmented DNA in each well using a high yield, low chimera formation protocol^[@R10]^. Lastly, all 384 wells are combined and an unsaturated polymerase chain reaction using primers common to the ligated adapters is employed to generate sufficient template for massively parallel short read sequencing platforms (see [Supplementary Methods](#SD3){ref-type="supplementary-material"}). The addition of the LFR pre-processing steps to the standard library process currently adds about \$100 to the reagent cost of our genome sequencing ([Supplementary Table 2](#SD5){ref-type="supplementary-material"}).

LFR libraries from 100pg of isolated DNA or directly from 10 cells {#S2}
==================================================================

As a demonstration of the power of LFR to determine an accurate diploid genome sequence we generated three libraries of Yoruban female HapMap sample NA19240, six libraries from European HapMap pedigree 1463 ([Supplementary Figure 5](#SD4){ref-type="supplementary-material"}), and a single library from Personal Genome Project (PGP) sample NA20431. Pedigree 1463 and NA19240 have been extensively studied in the HapMap Project^[@R28],[@R29]^, the 1,000 Genomes Project^[@R30]^, and our own efforts^[@R31]^. As a result, highly accurate haplotype information can be generated for these samples based on the redundant sequence data from familial samples. One NA19240 LFR library was made from 10 cells of the corresponding immortalized B-cell line, all other libraries were made from an estimated 100-130 pg (equivalent to 15-20 cells) of denatured high molecular weight genomic DNA ([Supplementary Figure 6](#SD4){ref-type="supplementary-material"} and [Supplementary Methods](#SD3){ref-type="supplementary-material"}). Libraries were analysed using Complete Genomics' sequencing platform^[@R10]^. 35-base mate-paired reads were mapped to the reference genome using a custom alignment algorithm^[@R10],[@R32]^ yielding on average more than 250 Gbs of mapped data with an average genomic coverage \>80x ([Table 1](#T1){ref-type="table"} and [Supplementary Table 3](#SD5){ref-type="supplementary-material"}). Analysis of the mapped LFR data shows two distinct characteristics attributable to MDA: slight underrepresentation of GC rich sequences ([Supplementary Figure 7](#SD4){ref-type="supplementary-material"}) and an increase in chimeric sequences ([Supplementary Table 3](#SD5){ref-type="supplementary-material"}). Additionally, coverage normalized across 100 kb windows was more variable ([Supplementary Figure 8](#SD4){ref-type="supplementary-material"}). Nevertheless, almost all genomic regions were covered with sufficient reads (5 or more) demonstrating that 10,000 fold MDA amplification by our optimized protocol can be used for comprehensive genome sequencing. Barcodes were used to group mapped reads based on their physical well location within each library resulting in sparse regions of coverage interspersed between long spans with almost no read coverage ([Supplementary Figure 9](#SD4){ref-type="supplementary-material"}). Each of these discrete regions of coverage represents a physical DNA fragment. On average, each well contained 10-20% of a haploid genome (300-600 Mb) in fragments ranging from 10 kb to over 300 kb in length with N50s of \~60 kb ([Table 1](#T1){ref-type="table"}). Initial fragment coverage was very uniform between chromosomes ([Supplementary Figure 10](#SD4){ref-type="supplementary-material"}). As estimated from all detected fragments, the total amounts of DNA used to make the two NA19240 libraries from extracted DNA were \~62 pg and 84 pg (equivalent to 9.4 and 12.7 cells). This is less than the expected 100-130 pg indicating some lost or undetected DNA or imprecision in DNA quantification. Interestingly, the 10-cell library appeared to be made from \~90 pg (13.6 cells) of DNA, most likely due to some of the cells being in S phase during isolation ([Table 1](#T1){ref-type="table"}).

LFR haplotyping results {#S3}
=======================

To ensure complete representation of the genome we maximized the input of DNA fragments for a given read coverage and number of aliquots ([Supplementary Materials](#SD2){ref-type="supplementary-material"} and [Supplementary Table 1](#SD5){ref-type="supplementary-material"}). Unlike other experimental approaches^[@R11],[@R13],[@R20]^, this resulted in low-coverage read data (\<2x) for each fragment in each of the \~40 wells a fragment is found in. This type of data is not useful for defining haplotypes for each initial fragment and required the development of a novel phasing algorithm that statistically combines reads from related fragments found in separate aliquots ([Supplementary Methods](#SD3){ref-type="supplementary-material"} and [Fig. 2](#F2){ref-type="fig"}). Application of our algorithm to the LFR libraries resulted in the placement of on average 92% of the phasable heterozygous SNPs into long contigs with N50s of \~1 Mb and \~ 500 kb for NA19240 and European samples, respectively ([Table1](#T1){ref-type="table"} and [Supplementary Table 4](#SD5){ref-type="supplementary-material"}). The large reduction in the N50 contig size for European samples can be explained by many more regions of low heterozygosity (RLHs, [Supplementary Tables 5](#SD5){ref-type="supplementary-material"}-[7](#SD5){ref-type="supplementary-material"}, [Supplementary Figure 11](#SD4){ref-type="supplementary-material"}, and [Supplementary Materials](#SD2){ref-type="supplementary-material"}) found in these genomes. Doubling the number of reads to \~160x coverage or combining replicate samples (a total of 768 independent wells), each with \~80x coverage, pushed the phasing rate to \~96% ([Table 1](#T1){ref-type="table"}). Using only the SNP loci called in the LFR library for phasing resulted mostly in a reduction in the total number of phased SNPs by 5-15% ([Table 1](#T1){ref-type="table"} and [Supplementary Materials](#SD2){ref-type="supplementary-material"}). Importantly, the 1.72 million heterozygous SNPs called and phased by the NA12892 LFR library alone was slightly higher than the number of SNPs phased for a comparable sample using a fosmid approach^[@R13],[@R20]^ ([Table 1](#T1){ref-type="table"}). For NA19240, the 10-cell library phased over 98% of variants phased by the two libraries made from isolated DNA demonstrating that LFR can be successful starting from a small number of cells.

LFR reproducibility and phasing error rate analysis {#S4}
===================================================

To test LFR reproducibility we compared haplotype data between the two NA19240 replicate libraries. In general, the libraries were very concordant, with only 64 differences per library in \~2.2 million heterozygous SNPs phased by both libraries ([Supplementary Table 8](#SD5){ref-type="supplementary-material"}) or 1 of this error type in 44 Mb. LFR was also highly accurate when compared to the conservative but accurate whole chromosome phasing generated from the parental genomes NA19238 and NA19239 previously sequenced by multiple methods^[@R28]-[@R31]^ ([Supplementary Table 4](#SD5){ref-type="supplementary-material"}). Only \~60 instances in 1.57 million comparable individual loci were found in which LFR phased a variant inconsistent with that of the parental haplotyping (false phasing rate of 0.002% if half of discordances are due to sequencing errors in parental genomes). The LFR data also contained \~135 contigs per library (2.2%) with one or more flipped haplotype blocks ([Supplementary Table 8](#SD5){ref-type="supplementary-material"}). Extending these analyses to the European replicate libraries of sample NA12877 ([Supplementary Table 8](#SD5){ref-type="supplementary-material"}) and comparing them with a recent high quality family-based analysis^[@R18]^ yielded similar results assuming each method contributes half of the observed discordance ([Supplementary Table 9](#SD5){ref-type="supplementary-material"}). In both NA19240 and NA12877 libraries several contigs had dozens of flipped segments. The majority of these contigs were located in regions of low heterozygosity, low read coverage regions, or repetitive regions observed in an unexpectedly large number of wells (*e.g.,* subtelomeric or centromeric regions). Most of these errors can be corrected by forcing the LFR phasing algorithms to end contigs in these regions. Alternatively, these errors can be removed with the simple, low cost addition of standard high density array genotype data (\~1 million or greater SNPs) from at least one parent to the LFR assembly. We found that parental genotypes can connect 98% of LFR phased heterozygous SNPs in full chromosome haplotypes. Additionally, this data allows haplotypes to be assigned to maternal and paternal lineages; information that is critical for incorporating parental imprinting in genetic diagnoses in any experimental haplotyping approach. If parental data is unavailable population genotype data could also be used to connect many of these LFR contigs, although at the cost of increased phasing errors^[@R17]^.

Phasing *de-novo* mutations {#S5}
===========================

As a demonstration of the completeness and accuracy of our diploid genome sequencing we assessed phasing of 35 *de-novo* mutations recently reported in the genome of NA19240^[@R33]^. 34 of these mutations were called in either the standard genome or one of the LFR libraries. Of those, 32 *de-novo* mutations were phased (16 coming from each parent) in at least one of the two replicate LFR libraries ([Supplementary Table 10](#SD5){ref-type="supplementary-material"}). Not surprisingly, the two non-phased variants reside in RLHs. Of these 32 variants, 21 were phased by Conrad *et al.*^[@R33]^ and 18 were consistent with LFR phasing results (Matthew Hurles personal communication). The three discordances are likely due to errors in the previous study (Matthew Hurles personal communication) confirming LFR accuracy, but not affecting the substantive conclusions of the report.

Error reduction enabled by LFR for accurate genome sequencing from 10 cells {#S6}
===========================================================================

Substantial error rates (\~1 SNV in 100-1,000 called kilobases) are a common attribute of all current massively parallelized sequencing technologies^[@R2]-[@R10],[@R18]^. These rates are most likely too high for diagnostic use and complicate many studies searching for novel mutations. The vast majority of errors are no more likely to occur on the maternal or paternal chromosome. This lack of consistent phasing or presence in only a few aliquots can be exploited by LFR to eliminate these errors from the final assembled haplotypes. To demonstrate this we defined a set of heterozygous SNPs in NA19240 and NA12877 LFR libraries that were reported with high confidence in each of the individual's parents as matching the human reference genome at both alleles (\>85% of all heterozygous SNPs). There were about 44,000 of these heterozygous SNPs in NA19240 and 30,000 in NA12877 that met this criterion. By virtue of their nonexistence in the parental genomes these variations are *de novo* mutations, cell line specific somatic mutations, or false positive variants. Approximately 1,000-1,500 of these variants were reproducibly phased in each of the two replicate LFR libraries from samples NA19240 and NA12877 ([Supplementary Table 11](#SD5){ref-type="supplementary-material"}). These numbers are similar to those previously reported for *de-novo* and cell line specific mutations in NA19240^[@R33]^. The remaining variants are likely to be initial false positives of which only about 500 are phased per library. This represents a 60 fold reduction of the false positive rate in those variations that are phased. Only \~2,400 of these false variants are present in the standard libraries, of which only \~260 are phased (\<1 false positive SNV in 20 Mb; 5700 haploid Mb / 260 errors). Each LFR library exhibits a 15 fold increase, compared to a genome sequenced by the standard process, in library specific false positive calls before phasing. The majority of these false positive SNVs are likely to have been introduced by MDA; sampling of rare cell-line variants may be responsible for a smaller percentage. Despite making LFR libraries from 100 pg of DNA and introducing a large number of errors through MDA amplification, applying the LFR phasing algorithm described above reduces the overall sequencing error rate to 99.99999% (\~600 false heterozygous SNVs/6 Gb), approximately 10 fold lower than the previous published error rates using the same ligation-based sequencing chemistry^[@R18]^. These accurate haplotypes allow detection of highly diverged human sequences ([Supplementary Materials](#SD2){ref-type="supplementary-material"} and [Supplementary Table 13](#SD5){ref-type="supplementary-material"}) and many other applications.

Many genes have putative inactivating variations in both alleles {#S7}
================================================================

To demonstrate how LFR could be used in a diagnostic/prognostic environment we analysed the coding SNP data of all libraries for two or more nonsense, splicesite, or PolyPhen2^[@R34]^ predicted detrimental missense variations that co-occur in the same gene. Of these, approximately 40 genes were found in each individual that contained a least one detrimental variation in each allele ([Table 2](#T2){ref-type="table"}). Extending this analysis to variants which disrupt transcription factor binding sites (TFBS) introduces an additional \~100 genes per individual (additional analyses of the effects of TFBS disruption on allele specific expression can be found in [Supplementary Materials](#SD2){ref-type="supplementary-material"} and [Supplementary Table 12](#SD5){ref-type="supplementary-material"}). Due to the high accuracy of LFR it is unlikely that these variants are a result of sequencing errors and many could have been introduced in the propagation of these cell lines. Further, some of these variants are likely to have little to no effect on the function of these gene products^[@R35]^ and much more work is required to understand how changes in TFBS sites effect transcription. A few of these variants were found in unrelated individuals suggesting that they could be improperly annotated or the result of a systematic mapping or reference error. The genome of NA19240 contained an additional \~10 genes predicted to have complete loss of function; this is most likely due to biases introduced by using a European reference genome to annotate an African genome. Nonetheless, these numbers are similar to those found in several recent studies on phased individual genomes^[@R13],[@R35],[@R36]^ and suggest that most generally healthy individuals probably have a small number of genes, not absolutely required for normal life, which encode ineffective protein products. Additional studies are required to understand the meaning of these types of changes. Importantly, we have demonstrated that LFR is able to identify genes in which two detrimental variants are found in different alleles without the need for costly verification^[@R35]^. This information is critical for effective clinical interpretation of patient genomes.

Discussion {#S8}
==========

In this study we have demonstrated the efficiency of LFR to accurately phase up to 97% of all detected heterozygous SNPs in a genome into long contiguous stretches of DNA (N50s 400-1500 kb in length). Even LFR libraries phased without candidate heterozygous SNPs from standard libraries, and thus using only 10-20 human cells, are able to phase \>90% of the available SNP. In several instances, the LFR libraries used in this paper had less than optimal starting input DNA (NA20431, [Table1](#T1){ref-type="table"}). Phasing rate improvements seen by combining two replicate libraries or starting with more DNA (NA12892, [Table 1](#T1){ref-type="table"}) agree with this conclusion. Additionally, underrepresentation of GC rich sequences resulted in less of the genome being called ([Supplementary Table 3](#SD5){ref-type="supplementary-material"}). Improvements to the MDA process, removal of amplification steps as future single molecule sequencing processes improve, or modifications to how we perform base and variant calling in LFR libraries will help increase the coverage in these regions (see [Supplementary Materials](#SD2){ref-type="supplementary-material"} and [Supplementary Figure 12](#SD4){ref-type="supplementary-material"} for a demonstration of how LFR can make calls in low coverage regions). Moreover, as the cost of whole genome sequencing continues to fall, higher coverage libraries, demonstrated in this paper to dramatically improve call rates and phasing, will become more affordable.

A consensus haploid sequence is sufficient for many applications; however it lacks two very important pieces of data for detecting disease causing variants in personal genomes: phased heterozygous variants and identification of false positive and negative variant calls. By providing sequence data from both the maternal and paternal chromosomes independently, LFR is able to detect regions in the genome assembly where only one allele has been covered. Likewise, false positive calls are avoided because LFR independently, in separate aliquots, sequences both the maternal and paternal chromosomes 10-20 times. The result is a statistically low probability that random sequencing or DNA amplification errors would repeatedly occur in several aliquots at the same base position on one parental allele. Thus, LFR allows, for the first time, both accurate and cost-effective sequencing of a genome from a few human cells in spite of the required extensive DNA amplification. Further, by phasing SNPs over hundreds of kilobases (or over entire chromosomes by integrating LFR with routine genotyping of at least one parent), LFR is able to more accurately predict the effects of compound regulatory variants and parental imprinting on allele specific gene expression and function in various tissue types. Additionally, separation of mate-pair reads by haplotype may also help in detecting expanded tri-nucleotide repeats in diseases like Huntingtons, even though LFR does not provide direct length measure of these or similar repeats. Taken together this provides a highly accurate report about the potential genomic changes that could cause gain or loss of protein function. This kind of information, obtained inexpensively for every patient, will be critical for clinical use of genomic data. Moreover, successful and affordable diploid sequencing of a human genome starting from ten cells opens the possibility for comprehensive and accurate genetic screening of micro biopsies from diverse tissue sources such as circulating tumor cells or pre-implantation embryos generated through *in vitro* fertilization.

Methods Summary {#S9}
---------------

High molecular weight DNA was purified from cell lines GM12877, GM12878, GM12885, GM12886, GM12891, GM12892 GM19240, and GM20431 (Coriell Institute for Medical Research, Camden, NJ) using a RecoverEase DNA isolation kit (Agilent, La Jolla, CA) following the manufacturer's protocol. Individual cells of NA19240 were isolated under 200x magnification with a micromanipulator (Eppendorf, Hamburg, Germany) and deposited into a 1.5 ml microtube with 10 ul of dH~2~O. LFR libraries were made as outlined in the main text; a more detailed description can be found in the [Supplementary Methods](#SD3){ref-type="supplementary-material"}. LFR libraries were sequenced, mapped, and assembled using the Complete Genomics' sequencing pipeline. Phasing was performed using custom haplotyping algorithms as described in [Figure 2](#F2){ref-type="fig"} and in further detail in the [Supplementary Methods](#SD3){ref-type="supplementary-material"}. Variations adversely affecting protein function or expression were found using several methods. Misssense variations were analyzed using Polyphen2^[@R34]^. For this study both "possibly damaging" and "probably damaging" were considered to be detrimental to protein function as were all nonsense mutations. Variations determined to adversely affect mRNA splicing were found with a custom algorithm based on consensus splice position models from Steve Mount's database^[@R37]^. JASPAR models^[@R38],[@R39]^ were used to extract potential TFBSs from the reference genome with mast^[@R40]^. Variations falling with these regions were compared to the models to determine what affect they had upon transcription factor binding. Genes found to have two or more detrimental mutations were only further analyzed if all mutations were found within the same haplotype contig. More detailed descriptions of all methods used in this paper can be found in the online [Supplementary Methods](#SD3){ref-type="supplementary-material"}.
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======================
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![Overview of the Long Fragment Read (LFR) technology and controlled random enzymatic (CoRE) fragmenting\
(a) 100-130 pg of high molecular weight DNA is physically separated into 384 distinct wells, (b) through several steps, all within the same well without intervening purifications, the genomic DNA is amplified, fragmented, and ligated to unique barcode adapters, (c) all 384 wells are combined, purified, and introduced into Complete Genomics' sequencing platform^[@R10]^, (d) mate-paired reads are mapped to the genome using a custom alignment program and barcode sequences are used to group tags into haplotype contigs, (e) the final result is a diploid genome sequence.](nihms-377834-f0001){#F1}

![LFR haplotyping algorithm\
(a) Variation extraction: Variations are extracted from the aliquot tagged reads. The 10-base Reed-Solomon codes enable tag recovery via error correction. (b) Heterozygous SNP-pair connectivity evaluation: The matrix of shared aliquots is computed for each heterozygous SNP-pair within a certain neighbourhood. Loop1 is over all the heterozygous SNPs on one chromosome. Loop2 is over all the heterozygous SNPs on the chromosome which are in the neighbourhood of the heterozygous SNPs in Loop1. This neighbourhood is constrained by the expected number of heterozygous SNPs and the expected fragment lengths. (c) Graph generation: An undirected graph is made, with nodes corresponding to the heterozygous SNPs and the connections corresponding to the orientation and the strength of the best hypothesis for the relationship between those SNPs. The orientation is binary and is shown in the figure with a colour. Red and green depict a flipped and unflipped relationship between heterozygous SNP pairs, respectively. The strength is defined by employing fuzzy logic operations on the elements of the shared aliquot matrix. (d) Graph optimization: The graph is optimized via a minimum spanning tree operation. (e) Contig generation: Each sub-tree is reduced to a contig by keeping the first heterozygous SNP unchanged, and flipping or not flipping the other heterozygous SNPs on the sub-tree, based on their paths to the first heterozygous SNP. The designation of Parent 1 (P1) and Parent 2 (P2) to each contig is arbitrary. The gaps in the chromosome-wide tree define the boundaries for different sub-trees/contigs on that chromosome. (f) Optional mapping of LFR contigs to parental chromosomes: Using parental information, a Mom or Dad label is placed on the P1 and P2 haplotypes of each contig.](nihms-377834-f0002){#F2}

###### Comparison of haplotyping performance between different genome assemblies

Variant calls for standard and LFR assembled libraries were combined and used as loci for phasing except where specified. Two samples were run with Complete Genomics' pipeline 2.0 algorithms which are expected to call more heterozygous SNPs, the remaining samples were analysed with previous versions (1.7-1.8) of Complete Genomics' algorithms. The LFR phasing rate was based on a calculation of parental phased heterozygous SNPs ([Supplementary Table 4](#SD5){ref-type="supplementary-material"}).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample                                       Ethnicity   Number of\      LFR\                                  Haploid\                                      Fragment Size for\   Fragment Size for\   DNA Bases\         N50 Contig\
                                                           Heterozygous\   Phasing\                              Fragment\                                     N50 DNA (kb)         N25 DNA (kb)         Sequenced (Gb),\   Length (kb)
                                                           Phased SNPs     Rate                                  coverage (cells)                                                                        LFR + STD          
  -------------------------------------------- ----------- --------------- ------------------------------------- --------------------------------------------- -------------------- -------------------- ------------------ -------------
  NA19240-Replicate 1                          Yoruban     2,386,741       91%                                   38 (9.4)                                      64                   84                   237+176            1,210

  NA19240-Replicate 2                          Yoruban     2,433,621       91%                                   51 (12.7)                                     66                   96                   313+176            1,010

  NA19240-10 cell pipeline 2.0                 Yoruban     2,369,433       89%                                   54.3 (13.6)[\#](#TFN2){ref-type="table-fn"}   80                   120                  308+176            943

  NA19240-Replicate 1 High Coverage            Yoruban     2,578,903       96%                                   48 (11.9)                                     82                   116                  509+176            1,429

  NA19240-Replicates 1&2 combined              Yoruban     2,646,352       97%                                   89 (22.1)                                     65                   90                   550+176            1,577

  NA19240-Replicate 1 LFR only pipeline 2.0    Yoruban     2,031,514       91%                                   38 (9.4)                                      64                   84                   237                1,036

  NA19240-Replicate 1 High Coverage LFR only   Yoruban     2,274,696       95%                                   48 (11.9)                                     82                   116                  509                1,282

  NA12877-Replicate 1                          European    1,831,032       93%                                   65 (16.3)                                     74                   104                  258+218            530

  NA12877-Replicate 2                          European    1,810,540       92%                                   51 (12.7)                                     76                   106                  238+218            535

  NA12877-Replicates 1&2 combined              European    1,946,089       97%                                   116 (29)                                      75                   105                  496+218            600

  NA12885                                      European    1,850,409       92%                                   46 (11.6)                                     72                   98                   272+221            528

  NA12886                                      European    1,854,360       93%                                   44 (11)                                       66                   88                   293+216            535

  NA12891                                      European    1,825,427       90%[\*](#TFN1){ref-type="table-fn"}   46 (11.6)                                     80                   112                  280+246            545

  NA12892                                      European    1,917,442       93%[\*](#TFN1){ref-type="table-fn"}   93 (23.3)                                     94                   138                  285+213            553

  NA12892 LFR only                             European    1,720,750       97%[\*](#TFN1){ref-type="table-fn"}   93 (23.3)                                     94                   138                  285                525

  NA20431 High Coverage                        European    1,703,047       84%[\*](#TFN1){ref-type="table-fn"}   30 (7.4)                                      94                   142                  514+189            411
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For those individuals without parental genome data (NA12891, NA12892, and NA20431) the phasing rate was calculated by dividing the number of phased heterozygous SNPs by the number of heterozygous SNPs expected to be real (number of attempted to be phased SNPs -- 50,000 expected errors). N50 calculations are based on the total assembled length of all contigs to the NCBI build 36 (build 37 in the case of NA19240 10 cell and high coverage and NA20431 high coverage) human reference genome. Haploid fragment coverage is four times greater than the number of cells as a result of all DNA being denatured to single stranded prior to being dispersed across a 384 well plate. The insufficient amount of starting DNA explains lower phasing efficiency in the NA20431 genome.

The 10 cell sample was measured by individual well coverage to contain more than 10 cells, this is likely the result of these cells being in various stages of the cell cycle during collection.

###### Number of genes with multiple detrimental variations in each analysed sample

All phased SNPs were analysed by PolyPhen2^[@R34]^ and a custom splice site detection algorithm ([Supplementary Methods](#SD3){ref-type="supplementary-material"}) to find variants with a high probability of coding for non-functional proteins. Only variants that were contained within the same contig for each gene were examined. Because LFR contigs are very long (N50\>500 kb) very few variants were excluded based on this criteria. In each gene 5 kb of the regulatory region upstream of the transcription start site and 1 kb downstream were scanned for SNVs that significantly altered over 300 transcription factor binding sites (TFBS)^[@R38],[@R39]^. These potentially detrimental variations in TFBSs were also phased with coding SNPs to create a more comprehensive list of genes whose function and/or expression might be altered in these individuals ([Supplementary Methods](#SD3){ref-type="supplementary-material"}).

  Sample                              Ethnicity   Coding Only   Coding and TFBS         
  ----------------------------------- ----------- ------------- ----------------- ----- -----
  NA19240 Replicate 1                 Yoruban     47            79                182   162
  NA19240 Replicate 2                 Yoruban     55            85                207   174
  NA19240-10 cell pipeline 2.0        Yoruban     62            86                197   156
  NA19240-Replicate 1 High Coverage   Yoruban     65            95                235   185
  NA19240-Replicates 1&2 combined     Yoruban     65            99                241   197
  NA12877 Replicate 1                 European    45            78                144   144
  NA12877 Replicate 2                 European    44            82                146   141
  NA12877-Replicates 1&2 combined     European    49            96                167   168
  NA12885                             European    34            79                143   141
  NA12886                             European    32            101               140   168
  NA12891                             European    36            69                130   140
  NA12892                             European    37            65                125   136
  NA20431 High Coverage               European    36            70                115   127

[^1]: Present Address: Aria Diagnostics, 5945 Optical Court, San Jose, CA 95138

[^2]: Present Address: Halo Genomics, Dag Hammarskjolds vag 54A, 751 83 Uppsala, Sweden

[^3]: These authors contributed equally to this work.
